The Autoimmune Registry
Myelin oligodendrocyte glycoprotein antibody-associated disease Graphs for this disease are generated based on data from the Autoimmune Registry Inc.
For more information on our data sources, please visit here.
For help with understanding the disease profile tabs and charts, please visit here.
  • Names
    • Myelin oligodendrocyte glycoprotein antibody-associated disease
    • Anti-MAG disease
    • Anti-MOG disease
    • MOG Antibody Disease
    • Myelin oligodendrocyte glycoprotein disease
    • Polyneuropathy associated with monoclonal immunoglobulin M antibodies to myelin-associated glycoprotein
    Abbreviations: MOG
    Category: Nervous System
    Prevalence From 5,332 to 11,398 cases in the US (Flanagan 2019). Female/Male ratio: 8.0x.
    Age of Onset Onset typically between 4 and 8 years old for children and between 30 and 40 years old for adults.
    Description Myelin oligodendrocyte glycoprotein disease (MOG) is a recently recognized condition marked by the presence of antibodies against myelin oligodendrocyte glycoprotein (MOG). The disease differs from multiple sclerosis (MS), aquaporin-4 (AQP4) antibody disease, and neuromyelitis optica spectrum disorders (NMOSD). MOG symptoms can range from those of neuromyelitis optica to acute demyelinating encephalomyelitis and cortical encephalitis. A correct diagnosis requires both specific and sensitive assays for the antibody. In brain images MOG overlaps with AQP4 antibody NMOSD but can be usually distinguished from MS. In particular, the silent lesions typical of MS that progressively increase lesion volume are rare in MOG antibody disease. Medium-term immunosuppression appears to be protective. Permanent disability, particularly severe ambulatory and visual disability, is less frequent than in AQP4 antibody NMOSD and usually results from the onset attack.

    Evidence of autoimmunity: Antibody


    Patient Groups
    Bloggers
      Symptoms
      Resources Link to Clinical Trials
      Link to PubMed
      References Link to Mayo Clinic
      Link to Cleveland Clinic
      Link to Healthline
      Profile by: Julie Farkas
    • Profile updated September 2024
    • Charts generated Oct 12, 2024 at 12:54 PM ET

    • Myelin oligodendrocyte glycoprotein antibody-associated disease sex breakdown


      Myelin oligodendrocyte glycoprotein antibody-associated disease age breakdown



      Join the registry!

      Graphs for this disease are generated based on data from the Autoimmune Registry Inc.

    • Myelin oligodendrocyte glycoprotein antibody-associated disease top autoimmune comorbidities


      Join the registry!

      * Disease is suspected as autoimmune, but unconfirmed.
      Data Source: Graphs on this page represent data from the Autoimmune Registry Inc. here. To protect participant anonymity, results derived from fewer than 5 participants are not graphed. The Autoimmune Registry Inc is a 501(c)(3) non-profit supported by donors like you.


    • Join the registry!

      * Biologic medications.
      Data Source: Graphs on this page represent data in electronic health records from the All of Us research database. As of July 2024, there are 451,000 sets of electronic health records collected from participants. A snapshot of the data can be found here. To protect participant anonymity, results derived from fewer than 20 participants are not graphed.
      The All of Us Research Program is supported by the National Institutes of Health, Office of the Director: Regional Medical Centers: 1 OT2 OD026549; 1 OT2 OD026554; 1 OT2 OD026557; 1 OT2 OD026556; 1 OT2 OD026550; 1 OT2 OD 026552; 1 OT2 OD026553; 1 OT2 OD026548; 1 OT2 OD026551; 1 OT2 OD026555; IAA #: AOD 16037; Federally Qualified Health Centers: HHSN 263201600085U; Data and Research Center: 5 U2C OD023196; Biobank: 1 U24 OD023121; The Participant Center: U24 OD023176; Participant Technology Systems Center: 1 U24 OD023163; Communications and Engagement: 3 OT2 OD023205; 3 OT2 OD023206; and Community Partners: 1 OT2 OD025277; 3 OT2 OD025315; 1 OT2 OD025337; 1 OT2 OD025276. In addition, the All of Us Research Program would not be possible without the partnership of its participants.


    • Join the registry!

      Data Source: Graphs on this page represent data in self-reported survey results from the All of Us research database. As of July 2024, there are 560,000 participants who have completed these surveys. This dataset, however, may not be representative of the US population. A snapshot of the data can be found here. To protect participant anonymity, results derived from fewer than 20 participants are not graphed.
      The All of Us Research Program is supported by the National Institutes of Health, Office of the Director: Regional Medical Centers: 1 OT2 OD026549; 1 OT2 OD026554; 1 OT2 OD026557; 1 OT2 OD026556; 1 OT2 OD026550; 1 OT2 OD 026552; 1 OT2 OD026553; 1 OT2 OD026548; 1 OT2 OD026551; 1 OT2 OD026555; IAA #: AOD 16037; Federally Qualified Health Centers: HHSN 263201600085U; Data and Research Center: 5 U2C OD023196; Biobank: 1 U24 OD023121; The Participant Center: U24 OD023176; Participant Technology Systems Center: 1 U24 OD023163; Communications and Engagement: 3 OT2 OD023205; 3 OT2 OD023206; and Community Partners: 1 OT2 OD025277; 3 OT2 OD025315; 1 OT2 OD025337; 1 OT2 OD025276. In addition, the All of Us Research Program would not be possible without the partnership of its participants.


    • Join the registry!

      Graphs for this disease are generated based on data from the Autoimmune Registry Inc.